Qi deficiency and blood stasis syndrome(Convalescence of ischemic stroke?stable coronary artery disease?diabetic peripheral neuropathy)
Conditions
Interventions
Group 2:Conventional treatment + Yi-Qi-Tong-Luo granule
Group 1:Conventional treatment + Yi-Qi-Tong-Luo granule placebo
Sponsors
Ethics Committee of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: Convalescence of ischemic stroke: (1) diagnosis of qi deficiency and blood stasis; (2) consistent with the western medical diagnosis of ischemic stroke; (3) aged between 35 and 80 years; (4) the onset is within 2 weeks to 3 months; (5) NIHSS score 4-22; (6) sign the informed consent. stable coronary artery disease: (1) diagnosis of qi deficiency and blood stasis syndrome; (2) in line with the western medicine stability of coronary heart disease angina pectoris I-III level diagnosis; (3) aged between 35 and 80 years; (4) signing the informed consent. Diabetic peripheral neuropathy: (1) diagnosed as qi deficiency and blood stasis; (2) meet the western diagnostic criteria for diabetic peripheral neuropathy; (3) between the ages of 35 and 80 years; (4) signing the informed consent.
Exclusion criteria
Exclusion criteria: Convalescence of ischemic stroke: (1) patients with stroke caused by brain tumors, brain trauma, and blood diseases; (2) patients with other diseases that affect the function of the limbs and affect the neurologic examination; (3) patients with severe hepatic and renal insufficiency (note: liver insufficiency refers to the value of ALT or AST greater than 2 times the normal upper limit;Renal insufficiency refers to blood creatinine value greater than 2 normal upper limit); (4) other diseases or psychoses that may affect patients' follow-up; (5) women who are pregnant or preparing for pregnancy or lactation; (6) those who are known to be allergic or severely allergic to the drug ingredients; (7) a witness with red tongue and thick tongue coating; (8) are participating in clinical trials of other drugs. Stable coronary artery disease: (1) patients with acute myocardial infarction, coronary heart disease in 3 month IV level/severe angina pectoris and other heart disease, other causes of chest pain; (2) patients with severe cardiopulmonary insufficiency, severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.); (3) patients with severe hepatic and renal insufficiency; (4) other diseases or psychoses that may affect patients' follow-up; (5) women who are pregnant or preparing for pregnancy or lactation; (6) those who are known to be allergic or severely allergic to the drug ingredients; (7) a witness with red tongue and thick tongue coating; (8) are participating in clinical trials of other drugs. Diabetic peripheral neuropathy: (1) acute and severe diabetes; (2) accompanied by severe heart and brain diseases; (3) patients with severe hepatic and renal insufficiency (note: liver insufficiency refers to the value of ALT or AST greater than 2 times the normal upper limit; (4) Severe renal insufficiency refers to patients with spinal cord injury, cervical and lumbar pushing (nerve root compression, spinal canal stenosis, cervical and lumbar degeneration) or cerebrovascular diseases sequelae, neuromuscular joint or muscle diseases; (5) neuropathy caused by other diseases; (6) other diseases or psychoses that may affect patients' follow-up; (7) women who are pregnant or ready for pregnancy or lactation; (8) those who are known to be allergic to or severely allergic to the drug ingredients; (9) a witness with red tongue and thick tongue coating; (10) are participating in clinical trials of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation scale of qi deficiency and blood stasis syndrome; | — |
Countries
China
Contacts
Public ContactGao Ying
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Outcome results
None listed